Bioprinting and Lab Automation · NASDAQ STOCKHOLM: BICO
BICO Group: CELLINK bioprinting and bioinks inside a restructuring life-science automation platform.
CELLINK combines extrusion and light-based bioprinters, bioinks, biomaterials and application protocols for 3D cell culture. The bottleneck is preserving cell viability, geometry and reproducibility while integrating printed models into pharmaceutical, biotech and academic workflows.
As of: 18 July 2026 · Profile: Bioprinting and laboratory workflow · Recommendation: None
Investor read
BICO delivered strong organic growth in Q1 2026, but remained loss-making. Net sales were SEK 329.9 million, organic growth was 11.0% and adjusted EBITDA improved to SEK −11.4 million from SEK −21.4 million.
The quarter included SEK 52.5 million of restructuring costs, of which SEK 30.2 million affected EBITDA. BICO also refinanced with €40 million of senior secured bonds and fully repaid SEK 1.008 billion of convertible debt.
CELLINK remains the clearest additive-manufacturing exposure inside the group. Its printers and bioinks support 3D cell models, tissue engineering, organoids and drug-discovery workflows. The investment outcome, however, depends more on portfolio focus, lab-automation demand, cost reduction, liquidity and sustainable profitability than on bioprinting industry narratives.
High-signal metrics
| Metric | Period | Investor interpretation |
|---|---|---|
| SEK 329.9M net sales | Q1 2026 | Down 1.4% reported but organic growth was 11.0%. |
| 54.1% gross margin | Q1 2026 | Down from 56.7% a year earlier. |
| SEK −11.4M adjusted EBITDA | Q1 2026 | Adjusted margin improved to −3.4% from −6.4%. |
| SEK −42.4M EBITDA | Q1 2026 | Restructuring costs materially affected reported profitability. |
| SEK 47.3M operating cash flow | Q1 2026 | Positive despite operating losses. |
| SEK −131.3M continuing net result | Q1 2026 | Loss narrowed from SEK −235.4M. |
| €40M senior secured bonds | January 2026 | Refinancing supports liquidity but increases secured-debt obligations. |
| 53,600+ instruments | Company disclosure, 2026 | Broad installed footprint across more than 65 countries. |
Bioprinting and workflow model
| Layer | Capability | Economic role |
|---|---|---|
| Extrusion bioprinting | BIO X, BIO X6 and BIO ONE systems | Flexible deposition of cell-laden hydrogels and biomaterials. |
| Light-based bioprinting | LUMEN X and BIONOVA X | Higher-resolution and in-well workflows for selected applications. |
| Bioinks | Hydrogels, extracellular-matrix materials and photocurable formulations | Creates recurring consumable revenue and application-specific performance. |
| Protocols | Printing parameters, photocuring and cell-handling guidance | Reduces experimental variability and adoption friction. |
| 3D cell culture | Organoids, tissue models and disease models | Supports drug discovery and translational research. |
| Lab automation | Biosero, SCIENION and adjacent BICO brands | Connects printed biological models with broader laboratory workflows. |
| Installed base | Academic, pharma and biotech laboratories | Supports service, consumables and workflow expansion opportunities. |
Why CELLINK controls a bioprinting bottleneck
- Cell viability: nozzle geometry, pressure, shear, temperature and curing must protect living cells.
- Bioink rheology: printability must be balanced with biological function and structural stability.
- Multi-material deposition: complex tissue models require controlled placement of cells and biomaterials.
- Photocuring: wavelength, irradiance and exposure affect fidelity and cell health.
- Reproducibility: pharmaceutical and biotech users need repeatable models across runs and laboratories.
- Protocol ecosystem: validated parameters and application notes reduce experimental development time.
- Workflow integration: value increases when printing connects to imaging, incubation, liquid handling and assay automation.
Financial materiality
Emerging: AM can influence a business line or the strategic thesis, but is not yet dominant.
Addithive scorecard
| Dimension | Assessment | Rationale |
|---|---|---|
| Pure-play | 3 / 5 | AM is a meaningful business or transaction exposure, but the company is not a clean pure play. |
| Bottleneck ownership | 3 / 5 | Credible capability, but viable alternatives or incomplete production proof constrain scarcity. |
| Evidence maturity | Pilot | Strongest evidence remains pilot, development or early-customer activity. |
| Financial materiality | Emerging | AM can influence a business line or the strategic thesis, but is not yet dominant. |
| Substitutability | Medium | Alternatives exist, but replacement requires workflow changes, requalification or integration effort. |
| Evidence confidence | High for cited operational evidence; lower for AM economics | Product, qualification and production claims are source-backed; AM-specific revenue and margin disclosure is often limited. |
Catalysts and thesis breakers
Catalysts
- Organic growth remaining positive across volatile research markets.
- Adjusted EBITDA crossing into sustainable profitability.
- Bioink and consumable growth increasing recurring revenue mix.
- Pharma and biotech adoption reducing dependence on academic budgets.
- CELLINK workflows integrating with BICO automation brands.
- Restructuring costs falling and gross margin recovering.
- More transparent business-area and CELLINK operating disclosure.
Thesis breakers
- Organic growth failing to translate into positive EBITDA.
- Academic funding pressure weakening instrument demand.
- Bioink attach and service revenue remaining too small.
- Restructuring costs persisting beyond the planned transition.
- Secured debt and interest burden reducing strategic flexibility.
- Further impairments or portfolio disposals.
- Bioprinting remaining a research tool without scaled commercial workflows.
Valuation context
BICO should be valued on the durability of organic growth, route to positive adjusted EBITDA, gross margin, operating cash flow, refinancing risk, portfolio quality and laboratory capital-spending recovery. Bioprinting technology alone cannot offset weak group economics.
A stronger bioprinting premium would require visible CELLINK growth, consumable attachment, pharma and biotech adoption, repeat workflow purchases and segment profitability. Until then, the equity remains a turnaround and execution case.
What to monitor
- Organic growth versus reported revenue.
- Gross margin and adjusted EBITDA progression.
- Restructuring costs and operating cash flow.
- Secured debt, interest burden and liquidity.
- CELLINK printer placements, bioink attach and recurring revenue if disclosed.
- Academic versus pharma and biotech demand.
- Integration of bioprinting with lab-automation workflows.
Evidence gaps
- CELLINK revenue, growth, margin and backlog are not separately disclosed.
- Bioprinter shipments, installed-base utilization and service revenue are unavailable.
- Bioink attach, reorder rates and customer concentration are unknown.
- Business-area profitability and restructuring savings require deeper report extraction.
- Current consensus, ownership, liquidity and positioning were not sourced.
Source ledger
- BICO Q1 2026 interim release — sales, organic growth, margins, restructuring, cash flow and financing.
- BICO quarterly figures — historical reported metrics.
- BICO financial targets — organic-growth, margin and leverage framework.
- CELLINK product portfolio — bioprinters, bioinks and applications.
- About CELLINK — business positioning and BICO relationship.
- BICO investor relations — strategy, current reports and group footprint.
Research conclusion
BICO offers one of the clearest listed bioprinting exposures, but the investment is currently a profitability and restructuring case.
CELLINK owns meaningful know-how across printers, bioinks and biological protocols. The bottleneck is scientifically real, yet shareholder value depends on converting that position into recurring consumables, pharma and biotech workflows, positive margins and disciplined capital structure.
Research use only. This page is not investment advice.
Return to the Public Additive Manufacturing Companies Directory →